DEINOVE integrates into its pipeline a candidate antibiotic ready to enter phase IIand intends to respond to a major health emergency

May 23, 2018
DEINOBIOTICS/DEINOVE

Emmanuel PETIOT, CEO of DEINOVE, stated: "The acquisition of BIOVERTIS and MORPHOCHEM materializes the integration within our portfolio of the compound MCB3837, which consolidates our position in the antibiotic field. With this product, we have significantly expanded our portfolio of antibiotic compounds in development with a molecule already in the clinical phase and we intend to provide a response to the therapeutic deadlock that is severe infections with Clostridium difficile, causing several tens of thousands of deaths each year. (...)"

Press Release available here: